Whole exome sequencing identified a de novo variant in the IDS gene in a patient with mild form of the Mucopolysaccharidosis type II

Document Type : Case Report

Authors
F. Asadi 1
M. S. Ashkuh 2
M. R. Asadi 3
1 Department of Molecular Genetics, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran; Tel.: (+98-71) 43311172; Fax: (+98-71) 43112201
2 Department of Neurology, Shiraz University of Medical Science, Shiraz, Iran.
3 Department of Speech Therapy, School of Rehabilitation, Arak University of Medical Sciences, Arak, Iran
Abstract
Mucopolysaccharidosis (MSII) is described as a metabolic disorder resulting from an enzymatic failure causing from mutations in IDS gene, MPSII is divided into two forms; mild and severe. The first form does not affect intelligence and patients show no neurologic involvements, usually survive for the fourth decade of life. In patients with severe form, death mostly occurs due to neurologic involvement during the second decade of life. We reported a case, a 31-year-old patient, clinically suspicious to MPS II which was primarily diagnosed by the presence of the increased levels of dermatan and heparan sulfate in urine and I2S deficiency in plasma. Whole exome sequencing was utilized to detect the disease-causing variant in our patient. A de novo mutation (c.253G>A, (p.A85T) in exon 3 of the IDS gene was identified, which probably can describe the mild form of MPSII and clinical manifestations observed in the patient.

Keywords

Subjects

1. Neufeld E, Muenzer J. The mucopolysaccharidoses In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. New York (NY): McGraw-Hill; 2001.
2. Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochemistry research international. 2012;2012.
3. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. The Journal of pediatrics. 2004;144(5):S27-S34.
4. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European journal of pediatrics. 2008;167(3):267-77.
5. WILsoN PJ, Meaney CA, Hopwood JJ, Morris CPJG. Sequence of the human iduronate 2-sulfatase (IDS) gene. 1993;17(3):773-5.
6. Flomen RH, Green EP, Green PM, Bentley DR, Giannelli FJHmg. Determination of the organisation of coding sequences within the iduronate sulphate sulphatase (IDS) gene. 1993;2(1):5-10.
7. Weatherall DJB. The inherited diseases of hemoglobin are an emerging global health burden. 2010;115(22):4331-6.
8. Ellard PTS. Emery's Elements of Medical Genetics 15th ed. Health Sciences: Elsevier 2016.
9. Froissart R, Da Silva IM, Maire IJAp. Mucopolysaccharidosis type II: an update on mutation spectrum. 2007;96:71-7.
10. Young I, Harper P, Newcombe R, Archer IJJomg. A clinical and genetic study of Hunter's syndrome. 2 Differences between the mild and severe forms. 1982;19(6):408-11.
11. Brusius-Facchin AC, Siebert M, Leão D, Malaga DR, Pasqualim G, Trapp F, et al. Phenotype-oriented NGS panels for mucopolysaccharidoses: Validation and potential use in the diagnostic flowchart. Genetics and molecular biology. 2019;42(1):207-14.
12. Alves S, Mangas M, Prata M, Ribeiro G, Lopes L, Ribeiro H, et al. Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations. Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism. 2006;29(6):743-54.
13. Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. American journal of medical genetics Part A. 2009;149(5):960-4.
14. Kim CH, Hwang HZ, Song SM, Paik KH, Kwon EK, Moon KB, et al. Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations. Human mutation. 2003;21(4):449-50.
15. Lin H-Y, Tu R-Y, Chern S-R, Lo Y-T, Fran S, Wei F-J, et al. Identification and Functional Characterization of IDS Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II). International journal of molecular sciences. 2020;21(1):114.
16. Amartino H, Ceci R, Masllorens F, Gal A, Arberas C, Bay L, et al. Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome). Molecular genetics and metabolism reports. 2014;1:401-6.
17. Gupta A, Uttarilli A, Dalal A, Girisha KM. Hunter syndrome with late age of presentation: clinical description of a case and review of the literature. Case Reports. 2015;2015:bcr2015209305.
Pathobiology Reserach
Volume 24, Issue 2
February 2021
Pages 35-40